Status:
COMPLETED
Preoperative Twice Daily Chemoradiation in Addition to Chemotherapy Prior to Surgery in Stage III Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Heidelberg University
Collaborating Sponsors:
University Hospital Muenster
Lung Clinic Hemer
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-69 years
Phase:
PHASE3
Brief Summary
Patients are randomized to (arm A) 3 cycles of cisplatin/etoposide, followed by hyperfractionated radiotherapy (hfRT)with concurrent carboplatin and vindesine then surgery and, if no or R1/2-resection...
Detailed Description
Patients are randomized to (arm A) 3 cycles of cisplatin 55 mg/m2 (d 1 + 4)/etoposide 100 mg/m2 (d 1-4), followed by hyperfractionated radiotherapy (hfRT; 45 Gy, 2x1.5 Gy/d) with concurrent carboplati...
Eligibility Criteria
Inclusion
- non-small cell lung cancer proven by histology
- stage IIIA / stage IIIB
- mediastinoscopy
- performance score ECOG 0,1
- predicted postoperative FEV 1 \> 1.0 l
Exclusion
- small cell lung cancer
- cardiac disability (NYHA III/IV)
- prior radio- or chemotherapy
- pregnancy
- other malignancy
Key Trial Info
Start Date :
October 1 1995
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00176137
Start Date
October 1 1995
End Date
September 1 2005
Last Update
April 22 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.